ArticleCureus2023
Long-Term Opiate Therapy-Induced Secondary Adrenal Insufficiency: A Distinct Differential Diagnosis That Should Be Considered.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain management with opioid medication is associated with several side effects. Opioid-induced adrenal insufficiency by suppression of the hypothalamic-pituitary-adrenal (HPA) axis is one of them that needs to be considered. The possible effects of opioid use on adrenal function are addressed in this case report. This is a case of a 21-year-old female patient with sickle cell disease who started, for the last year, on extended-release morphine sulfate 45mg daily in an attempt to control the severity of her pain and frequent admission with the vaso-occlusive crisis. She presented with a sepsis-like presentation and received vasopressor, empiric antibiotics, and glucocorticoid. She experienced low blood pressure and low blood glucose after weaning off of steroids. A diagnosis of secondary adrenal insufficiency was established after comprehensive reevaluation and confirmed by morning cortisol value and ACTH stimulation test. Her long-term use of opioids was considered the underlying cause of her secondary adrenal insufficiency after the exclusion of other causes and the normal pituitary gland on the brain magnetic resonance image. She received maintenance hydrocortisone. On follow-up, the patient showed effective improvement, and her adrenal function recovered after discontinuation of the morphine over the following six months. In conclusion, OIAI is an under-recognized condition of adrenal insufficiency secondary to long-term exposure to opioids. OIAI can cause symptoms and may result in potentially life-threatening adrenal crises, but it can be managed. A direct detrimental impact on the hypothalamus and pituitary gland mostly causes the suppression of cortisol secretion by opioids. Understanding how to diagnose and treat OIAI is crucial, particularly since opioids are widely used. To determine the frequency and clinical importance of opioid-induced adrenal insufficiency and if hormone replacement therapy is necessary, more research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.